Cempra's lead oral antibiotic meets main goal in late-stage trial

January 5, 2015 10:22 AM

16 0

Jan 5 (Reuters) - Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial.

The drug is a next-generation version of a class of oft-prescribed antibiotics called macrolides, which are used to fight pathogens that cause community-acquired bacterial pneumonia (CAPB).

Also read: ZTE shares rise in Hong Kong after clarification of U.S. bill impact

Read more

To category page